A Phase I trial of NaV 1.8 inhibitor for acute and chronic pain conditions
Latest Information Update: 02 Mar 2026
At a glance
- Drugs NaV-1.8-inhibitor-Grunenthal (Primary)
- Indications Pain
- Focus Adverse reactions
Most Recent Events
- 02 Mar 2026 New trial record
- 18 Feb 2026 According to Grunenthal media release, first healthy volunteers have been enrolled in this study. Full results of the trial are expected in the second half of 2026.